Mechanisms of Ctla-4-ig in Tolerance Induction.
From: Department of Medicine, Section of Rheumatology, University of Chicago, IL 60637, USA. malegre@midway.uchicago.edu
Current pharmaceutical design
- Publish Date: 2006
- ISSN: 1381-6128
- Volume: 12
- Issue: 2
- Pages: 149-60
- Medium: Print
- Language: English
- Citation (JAMA): Alegre M-L, Fallarino F, et al. Mechanisms of Ctla-4-ig in Tolerance Induction.. Curr. Pharm. Des. 2006;12:149-60
Abstract
The size of the peripheral T lymphocyte pool remains relatively constant throughout adult life, but individual populations undergo expansion and contraction upon antigen encounter due to signals delivered by members of the B7-CD28 family of costimulatory molecules. This family includes receptors on T cells that can provide either activating or inhibitory signals. In general, activation occurs in response to pathogens, when lymphocyte expansion and acquisition of effector functions is appropriate. Conversely inhibitory receptors provide down-modulating signals that help terminate immune responses and maintain self-tolerance. The activating receptor CD28 engages the same B7-1 and B7-2 molecules as the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4), although with reduced affinity than CTLA-4. In addition to this direct competitive mechanism, CTLA-4 can directly inhibit T cell receptor (TCR) signals independently of CD28 expression and recent findings indicate that CTLA-4 may also operate through reverse signaling on ligand-expressing cells. Fusion proteins between the extracellular domain of CTLA-4 and an immunoglobulin Fc portion have been created that have potent immunosuppressive properties in animal models of transplantation and autoimmunity and that show great promise in clinical trials. Like CTLA-4, CTLA-Ig, is thought to selectively prevent activation of CD28 by interacting with B7-1 and B7-2. In addition, CTLA-4-Ig can bind to B7 molecules expressed on dendritic cells and activate a pathway of tryptophan catabolism that can lead to indirect inhibition of lymphocyte activation and T cell death. In this review, we will focus on the current knowledge of the mechanisms of action of CTLA-4 and CTLA-4-Ig.
Mesh Headings (Keywords): Animals, Antigens, CD28, Autoimmune Diseases, Clinical Trials as Topic, Humans, Immune Tolerance, Immunoconjugates, Immunosuppressive Agents, Lymphocyte Activation, T-Lymphocytes
Check for Full Text / PubMed Unique Identifier (PMID): 16454732
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.